IP Library Granted Patent US 9,174,971
Granted Patent B2
US 9,174,971 · App. 12/904,233 · Granted Nov 3, 2015

Process for the preparation of compounds useful as inhibitors of SGLT2

Inventors: Vittorio Farina (Beerse, BE); Sebastien François Emmanuel Lemaire (Brussels, BE); Ioannis N. Houpis (Antwerp, BE)
Assignee: Janssen Pharmaceutica NV
C07D409/14C07D309/10C07D409/10C07F3/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,174,971
App. No.
12/904,233
Granted
Nov 3, 2015
Kind
B2
Abstract

The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.

Claims (67)

1. A process for the preparation of compounds of formula (I)

wherein Ring A and Ring B are one of the following:

(1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; or

(2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, or an optionally substituted unsaturated fused heterobicyclic ring wherein Y is linked to the heterocyclic ring of the fused heterobicyclic ring; or

(3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, wherein the sugar moiety X-(sugar) and the moiety —Y-(Ring B) are both on the same heterocyclic ring of the fused heterobicyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring;

X is a carbon atom;

Y is —(CH 2 ) n —; wherein n is 1 or 2;

provided that in Ring A, X is part of an unsaturated bond;

or a pharmaceutically acceptable salt or solvate thereof; comprising

reacting a compound of formula (VII), wherein M 2 is a zinc species, with a compound of formula (VIII), wherein each Z is pivaloyl and wherein LG 2 is bromo; in a mixture of an ether solvent and a hydrocarbon solvent; wherein the ether solvent is selected from the group consisting of di-n-butyl ether and cyclopentylmethyl ether; at a temperature in the range of from about 60° C. to about 95° C.; to yield the corresponding compound of formula (IX);

de-protecting the compound of formula (IX); to yield the corresponding compound of formula (I).

2. A process as in claim 1 , further comprising

reacting a compound of formula (V), wherein LG 1 is a leaving group, with an organo-lithium reagent; in a mixture of an ether solvent and a hydrocarbon solvent; wherein the ether solvent is selected from the group consisting of di-n-butyl ether and cyclopentylmethyl ether; to yield the corresponding compound of formula (VI), wherein M 1 is lithium;

reacting the compound of formula (VI) with a zinc salt or an amine complex of zinc halide; wherein the ether solvent is selected from the group consisting of di-n-butyl ether and cyclopentylmethyl ether; in a mixture of an ether solvent and a hydrocarbon solvent; to yield the corresponding compound of formula (VII).

3. A process as in claim 1 , wherein M 2 is ZnBr.

4. A process as in claim 1 , wherein the compound of formula (VIII) is present in an amount in the range of from about 1.0 to about 1.1 molar equivalents.

5. A process as in claim 1 , wherein the hydrocarbon solvent is toluene.

6. A process as in claim 2 , wherein the organo-lithium reagent is n-hexyl lithium; and wherein the n-hexyl lithium is present in an amount in the range of from about 1.0 to about 1.2 molar equivalents.

7. A process as in claim 2 , wherein the hydrocarbon solvent is toluene.

8. A process as in claim 2 , wherein the zinc salt is selected from the group consisting of zinc dibromide (ZnBr 2 ), zinc diiodide (ZnI 2 ) and zinc ditriflate; and wherein the amine complex of zinc halide is selected from the group consisting of pyridine zinc bromide complex and N-methylmorpholine zinc bromide complex.

9. A process as in claim 2 , wherein the compound of formula (VI) is reacted with a zinc salt; wherein the zinc salt is zinc dibromide and wherein the zinc dibromide is present in an amount in the range of from about 0.33 to about 1.0 molar equivalents.

10. A process as in claim 1 , wherein

X is a carbon atom;

Ring A is selected from the group consisting of 4-methylphenyl and 4-chlorophenyl;

Y is —CH 2 — and is bound at the 3-position of Ring A; and

Ring B is selected from the group consisting of 2-(5-(4-fluorophenyl)-thienyl) and 2-(5-(6-fluoro-pyrid-3-yl)thienyl).

11. A process as in claim 1 , wherein X is a carbon atom; Ring A is 4-methyl-phenyl; Y is —CH 2 — and is bound at the 3-position of Ring A; and

Ring B is 5-(4-fluorophenyl)-thien-5-yl.

12. A process for the preparation of a compound of formula (I-S)

or solvate thereof; comprising

reacting a compound of formula (VII-S), wherein M 2 is a zinc species, with a compound of formula (VIII-S), wherein each Z is pivaloyl and wherein LG 2 is bromo; in a mixture of an ether solvent and a hydrocarbon solvent; wherein the ether solvent is selected from the group consisting of di-n-butyl ether and cyclopentylmethyl ether; at a temperature in the range of from about 60° C. to about 95° C.; to yield the corresponding compound of formula (IX-S);

de-protecting the compound of formula (IX-S); to yield the corresponding compound of formula (I-S).

13. A process as in claim 12 , wherein M 2 is ZnBr.

14. A process as in claim 12 , wherein the compound of formula (VIII-S) is present in an amount in the range of from about 0.8 to about 1.25 molar equivalents.

15. A process as in claim 14 , wherein the compound of formula (VIII-S) is present in an amount in the range of from about 1.0 to about 1.1 molar equivalents.

16. A process as in claim 12 , wherein the hydrocarbon solvent is toluene.

17. A process as in claim 12 , wherein the compound of formula (VIII-S) in a solution of the hydrocarbon solvent is added to the compound of formula (VII-S) in a solution of the ether solvent.

18. A process as in claim 12 , further comprising

reacting a compound of formula (V-S), wherein LG 1 is a leaving group; with an organo-lithium reagent; in a mixture of an ether solvent and a hydrocarbon solvent; wherein the ether solvent is selected from the group consisting of di-n-butyl ether and cyclopentylmethyl ether; to yield the corresponding compound of formula (VI-S), wherein M 1 is lithium;

reacting the compound of formula (VI-S) with a zinc salt or an amine complex of zinc halide; in a mixture of an ether solvent and a hydrocarbon solvent; wherein the ether solvent is selected from the group consisting of di-n-butyl ether and cyclopentylmethyl ether; to yield the corresponding compound of formula (VII-S).

19. A process as in claim 18 , wherein the organo-lithium reagent is n-hexyl lithium.

20. A process as in claim 18 , wherein the organo-lithium reagent is present in an amount in the range of from about 0.5 to about 2.0 molar equivalents.

21. A process as in claim 20 , wherein the organo-lithium reagent is present in an amount in the range of from about 1.0 to about 1.2 molar equivalents.

22. A process as in claim 18 , wherein the hydrocarbon solvent is toluene.

23. A process as in claim 18 , wherein the compound of formula (V-S) is reacted with the organo-lithium reagent at a temperature in the range of from about −78° C. to about room temperature.

24. A process as in claim 18 , wherein the zinc salt is selected from the group consisting of zinc dibromide (ZnBr 2 ), zinc diiodide (ZnI 2 ) and zinc ditriflate; and wherein the amine complex of zinc halide is selected from the group consisting of pyridine zinc bromide complex and N-methylmorpholine zinc bromide complex.

25. A process as in claim 18 , wherein the compound of formula (VI-S) is reacted with a zinc salt; and wherein the zinc salt is zinc dibromide.

26. A process as in claim 25 , wherein the zinc dibromide is present in an amount in the range of from about 0.33 to about 1.0 molar equivalents.

27. A process as in claim 26 , wherein the zinc dibromide is present in an amount of about 0.5 molar equivalents.

28. A process as in claim 18 , wherein the compound of formula (VI-S) is reacted with a zinc salt in the presence of an amine or lithium salt.

29. A process as in claim 28 , wherein the amine or lithium salt is selected from the group consisting of lithium bromide, lithium iodide, pyridine, N-methyl morpholine, 2,6-lutidine and TMEDA.

30. A process for the preparation of a compound of formula (X-P)

wherein both Q 1 groups are the same and are

and wherein Ring A and Ring B are one of the following:

(1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; or

(2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, or an optionally substituted unsaturated fused heterobicyclic ring wherein Y is linked to the heterocyclic ring of the fused heterobicyclic ring; or

(3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, wherein the sugar moiety X-(sugar) and the moiety —Y-(Ring B) are both on the same heterocyclic ring of the fused heterobicyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring;

X is a carbon atom;

Y is —(CH 2 ) n —; wherein n is 1 or 2;

provided that in Ring A, X is part of an unsaturated bond;

reacting a compound of the formula (Z1), wherein Ha 2 is a halogen, with a lithium trialkyl magnesate, a compound of formula (Z2); in a suitably selected anhydrous organic solvent or mixture or anhydrous organic solvents; to yield the corresponding compound of formula (Z3);

reacting the compound of formula (Z3) with a zinc halide.lithium halide complex, a compound of formula (Z4), wherein Ha 1 is a halogen; in a suitably selected anhydrous organic solvent or mixture or anhydrous organic solvents; to yield the corresponding compound of formula (X-P).

31. A process as in claim 30 , wherein the compound of formula (Z2) is lithium dibutyl hexylmagnesate; and wherein the compound of formula (Z4) is zinc bromide.lithium bromide complex.

32. A process as in claim 30 , wherein the compound of formula (X-P) is a compound of formula (X-S)

33. A process as in claim 1 , wherein the hydrocarbon solvent is selected from the group consisting of toluene, fluorobenzene, cholorbenzene and benzotrifluoride.

34. A process as in claim 12 , wherein the hydrocarbon solvent is selected from the group consisting of toluene, fluorobenzene, chlorobenzene and benzotrifluoride.

35. A process as in claim 29 , wherein the amine or lithium salt is present in an amount in the range of from about 1.0 to about 2.0 molar equivalent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2010
From: FARINA, VITTORIO; LEMAIRE, SEBASTIEN FRANCOIS EMMANUEL; HOUPIS, IOANNIS N.
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 025342/0681 →
Continuity (2)
Provisional Application 61251378 · Oct 14, 2009
Related Publication 20110087017A1 · Apr 14, 2011